Locate Therapeutics secures £2 million to fast-track development of innovative cell therapy programs5 Jun 2018
TAOS matrix system and products hailed as potential ‘game changers’ in the field of regenerative medicine.
Regenerative medicine company, Locate Therapeutics, has closed a £2 million finance package that will help the firm to fast-track its innovative TAOS matrix system and products for spinal fusion and bone regeneration.
The TAOS injectable scaffold matrix system from Locate is a unique regenerative medicine platform that provides an optimal structure to support tissue repair, and can precisely accommodate and promote the actions of regenerative drugs, and emergent cell-based therapies. The injectable particulate formulation of TAOS is thermally-triggered to solidify into a space-filling open porous depot that supports tissue repair before degrading away.
Locate has additional complementary technologies in cell therapy including Intrastem for intracellular delivery of proteins, nucleic acids and particles into cells.
Explaining the implications of this investment, Dr Ian Wilding, Chairman of Locate Therapeutics, said: “We are extremely excited about the potential of our drug delivery technologies to be ‘game changers’ in the field of regenerative medicine, opening up new products to change the lives of patients with severe illnesses. Our company has successfully transitioned from the research to development phase in the last three years and we welcome the backing of Mercia Fund Managers as our investment partner in our journey to commercialisation.
Commenting on the deal completion, Julian Dennard, Investment Director at Mercia, said: “To be able to support innovative firms such as Locate Therapeutics is a key driver for Mercia Fund Managers. This is a great example of how finance available through the MEIF can be leveraged with private money to bring needed capital to a potentially high growth life sciences’ business. We look forward to working with Locate Therapeutics and its partners to drive the business forward, allowing patients to benefit from new treatments by building an exciting next generation drug delivery business.”
Headquartered within MediCity in Nottingham, Locate Therapeutics, a spinout from the University of Nottingham, is leading the way in the development of targeted drug and stem cells delivery systems. This approach enables surgeons to administer stem cells and regenerative drugs to exact locations within the body to maximise efficacy and eliminate safety issues.
New formulation modelling successes using ex vivo tissue
9 Oct 2018
One study uses the company's proprietary TurChub model, to evaluate the diffusion and subsequent activity of drugs in human nails.Read more
Three-way collaboration to advance gene therapy
4 Oct 2018
Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.Read more
New oral treatment for metastatic melanoma receives EU authorisation
24 Sep 2018
Encorafenib in combination with binimetinib demonstrated 14.9 months median progression-free survival compared with vemurafenib monotherapy (7.3 months).Read more
Plasticell wins military contract to develop regenerative medicines for the battlefield
4 Sep 2018
Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.Read more
New biopharmaceutical testing laboratory to open in Geneva
28 Aug 2018
SGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.Read more
Exosome isolation manufacturing and characterization
13 Aug 2018
New service to reliably and reproducibly isolate exosomes from almost any biofluid.Read more
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines
8 Aug 2018
Company moves away from manual processing in favour of automated, scalable platforms.Read more
A new era for migraine patients
6 Aug 2018
EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.Read more
WuXi STA and Antengene sign development and manufacturing agreement
24 Jul 2018
WuXi STA chosen for its end-to-end CMC platform for new drug development.Read more
ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project
18 Jul 2018
Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation